Munir Muhammad Usman, Ikraam Mahnoor, Nadeem Muhammad, Khalid Syed Haroon, Asghar Sajid, Khalid Ikrima, Irfan Muhammad, Islam Nayyer, Ajaz Nyla, Khan Ikram Ullah
Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University Sakaka, Aljouf 72388, Saudi Arabia.
Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Government College University Faisalabad, Faisalabad 38000, Pakistan.
Pharmaceuticals (Basel). 2022 Jul 12;15(7):856. doi: 10.3390/ph15070856.
The aim of this study was to improve the solubility and prevent the ulcerogenic effect of flurbiprofen. Initially, binary and ternary solid dispersions (BSDs and TSDs) of flurbiprofen were prepared by using non-ordered mesoporous silica and gelucire. After preformulation testing (solubility, flow properties, % yield, and entrapment efficiency), four formulations were selected for further detailed studies. Solid-state characterization of optimized formulations (S1, S6, S7, and S12) showed successful drug incorporation in the solid dispersion at the molecular state without any noticeable interactions. The in vitro solubility and release study showed an increase in solubility and 98-100% of drug release in 30-45 min. The in vivo gastro-protective effect of the optimized formulations containing flurbiprofen and silica (1:1) with 25% / gelucire (S6 and S12) showed a reduction in the gastric lesion index (GLI) after four days of treatment. Moreover, histological images of the stomach lining (S6 and S12) illustrated normal epithelial cells and a partially protected mucosal membrane. Thus, TSD exhibited a significant increase in solubility and the dissolution rate and reduced the gastric ulceration. Therefore, TSDs are dubbed as efficacious carriers to enhance the bioavailability of flurbiprofen while simultaneously reducing its side effects.
本研究的目的是提高氟比洛芬的溶解度并防止其致溃疡作用。最初,通过使用无序介孔二氧化硅和 Gelucire 制备了氟比洛芬的二元和三元固体分散体(BSD 和 TSD)。经过处方前测试(溶解度、流动性、产率百分比和包封率)后,选择了四种制剂进行进一步的详细研究。优化制剂(S1、S6、S7 和 S12)的固态表征表明,药物成功以分子状态掺入固体分散体中,没有任何明显的相互作用。体外溶解度和释放研究表明,溶解度增加,在 30 - 45 分钟内药物释放率达到 98 - 100%。含氟比洛芬和二氧化硅(1:1)与 25% / Gelucire 的优化制剂(S6 和 S12)的体内胃保护作用显示,治疗四天后胃损伤指数(GLI)降低。此外,胃黏膜的组织学图像(S6 和 S12)显示上皮细胞正常,黏膜部分得到保护。因此,TSD 的溶解度和溶解速率显著增加,胃溃疡形成减少。所以,TSD 被认为是提高氟比洛芬生物利用度同时降低其副作用的有效载体。